Biomoda Awarded Patent Expanding Use of CyPath® Assay ALBUQUERQUE, N.M.–(BUSINESS WIRE)– Cancer diagnostics company Biomoda, Inc. (OTC BB:BMOD) received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath® assay to include patient response to cancer therapy during the treatment phase of the disease. “Our pilot clinical study demonstrated […]